Table 1

Baseline characteristics (mean (SD) or percentages) of patients with PsA starting their first TNFi as monotherapy or in combination with a csDMARD, pooled across all countries

TNFi and csDMARD co-medicationTNFi monotherapy
Proportion missing dataProportion missing data
N (%)9440 (62%)5892 (38%)
Age, years, mean (SD)48.9 (12.1)0%49.0 (12.6)0%
Sex (male), %50%0%48%0%
Disease duration, years mean (SD)6.3 (7.1)28%6.2 (7.3)32%
CRP, mg/L, mean (SD)13.6 (21.3)18%9.1 (16.9)25%
Tender joints 28, mean (SD)6.2 (5.9)21%5.6 (6.1)32%
Swollen joints 28, mean (SD)3.9 (4.2)21%2.9 (4.0)32%
VAS global health, mm, mean (SD)59.2 (24.0)21%58.1 (25.6)28%
VAS pain, mm, mean (SD)57.4 (23.6)30%56.3 (25.7)34%
DAPSA28, mean (SD)28.8 (16.0)38%26.0 (16.9)46%
DAS28-CRP, mean (SD)4.2 (1.2)29%3.8 (1.3)41%
Type of TNFi
 Adalimumab, %32%33%
 Certolizumab pegol, %6%4%
 Etanercept, %30%40%
 Golimumab, %11%10%
 Infliximab, %20%13%
Type of csDMARD used as co-medication
 Methotrexate, %79%
 Sulfasalazine, %15%
 Leflunomide, %11%
 Other*, %6%
  • *See the list of all csDMARDs in Methods section.

  • CRP, C reactive protein; csDMARD, conventional synthetic disease modifying anti-rheumatic drugs; DAPSA28, disease activity index for psoriatic arthritis with 28 joints; DAS28-CRP, disease activity score with 28 joints and CRP; PsA, psoriatic arthritis; TNFi, tumour necrosis factor inhibitors; VAS, visual analogue scale.